Your browser doesn't support javascript.
loading
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
Loriot, Yohann; Miller, Kurt; Sternberg, Cora N; Fizazi, Karim; De Bono, Johann S; Chowdhury, Simon; Higano, Celestia S; Noonberg, Sarah; Holmstrom, Stefan; Mansbach, Harry; Perabo, Frank G; Phung, De; Ivanescu, Cristina; Skaltsa, Konstantina; Beer, Tomasz M; Tombal, Bertrand.
Afiliação
  • Loriot Y; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: yohann.loriot@gustaveroussy.fr.
  • Miller K; Department of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Sternberg CN; Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy.
  • Fizazi K; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
  • De Bono JS; Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, London, UK.
  • Chowdhury S; Department of Urology, Guys and St Thomas' Hospital, London, UK.
  • Higano CS; Department of Medicine, Division of Medical Oncology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Noonberg S; Department of Early Clinical Development, Medivation, San Francisco, CA, USA.
  • Holmstrom S; Health Economics and Outcomes Research, Astellas Pharma Europe, Leiden, Netherlands.
  • Mansbach H; Department of Medical Affairs, Medivation, San Francisco, CA, USA.
  • Perabo FG; Astellas Pharma Global Development, Northbrook, IL, USA.
  • Phung D; Astellas Pharma Global Development, Northbrook, IL, USA.
  • Ivanescu C; Consulting, Quintiles, Hoofddorp, Netherlands.
  • Skaltsa K; Consulting, Quintiles, Barcelona, Spain; Department of Public Health, University of Barcelona, Barcelona, Spain.
  • Beer TM; Division of Hematology and Medical Oncology, OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • Tombal B; Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Lancet Oncol ; 16(5): 509-21, 2015 May.
Article em En | MEDLINE | ID: mdl-25888263
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor / Feniltioidantoína / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adolescent / Adult / Aged / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor / Feniltioidantoína / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adolescent / Adult / Aged / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article